L-type Ca2+ channel blocker that displays higher vascular selectivity than felodipine (Cat. No. 2960). Causes peripheral vasodilation with only weak negative inotropic activity. Antihypertensive.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 648.19. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.54 mL||7.71 mL||15.43 mL|
|5 mM||0.31 mL||1.54 mL||3.09 mL|
|10 mM||0.15 mL||0.77 mL||1.54 mL|
|50 mM||0.03 mL||0.15 mL||0.31 mL|
References are publications that support the products' biological activity.
Bang et al (2003) Lercanidipine. A review of its efficacy in the management of hypertension. Drugs 63 2449 PMID: 14609358
Wirtz and Herzig (2004) Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine. Br.J.Pharmacol. 142 275 PMID: 15155536
If you know of a relevant reference for Lercanidipine hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Lercanidipine hydrochloride, supplier, Ca2+, channel, blockers, L-type, Calcium, CaV, Channels, L-Type, voltage-gated, voltage-dependent, Voltage-gated, Calcium, Channels, Voltage-gated, Calcium, Channels, Tocris Bioscience
Citations for Lercanidipine hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Lercanidipine hydrochloride. Do you know of a great paper that uses Lercanidipine hydrochloride from Tocris? If so please let us know.
Lercanidipine hydrochloride Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.